Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
NCT01553786
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
80
Enrollment
OTHER
Sponsor class
Conditions
T-cell Lymphoma
Interventions
DRUG:
Lenalidomide
Sponsor
The Lymphoma Academic Research Organisation